Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine

Abstract

The two fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine (4F-Cy-BAP) and furanoyl-1-benzyl-4-anilinopiperidine (Fu-BAP) have recently been seized as new psychoactive substances (NPS) on the drugs of abuse market. As their toxicokinetic and toxicodynamic characteristics are completely unknown, this study focused on elucidating their in vitro metabolic stability in pooled human liver S9 fraction (pHLS9), their qualitative in vitro (pHLS9), and in vivo (zebrafish larvae) metabolism, and their in vitro isozyme mapping using recombinant expressed isoenzymes. Their maximum-tolerated concentration (MTC) in zebrafish larvae was studied from 0.01 to 100 µM. Their µ-opioid receptor (MOR) activity was analyzed in engineered human embryonic kidney (HEK) 293 T cells. In total, seven phase I and one phase II metabolites of 4F-Cy-BAP and 15 phase I and four phase II metabolites of Fu-BAP were tentatively identified by means of liquid chromatography high-resolution tandem mass spectrometry, with the majority detected in zebrafish larvae. N-Dealkylation, N-deacylation, hydroxylation, and N-oxidation were the most abundant metabolic reactions and the corresponding metabolites are expected to be promising analytical targets for toxicological analysis. Isozyme mapping revealed the main involvement of CYP3A4 in the phase I metabolism of 4F-Cy-BAP and in terms of Fu-BAP additionally CYP2D6. Therefore, drug-drug interactions by CYP3A4 inhibition may cause elevated drug levels and unwanted adverse effects. MTC experiments revealed malformations and changes in the behavior of larvae after exposure to 100 µM Fu-BAP. Both substances were only able to produce a weak activation of MOR and although toxic effects based on MOR activation seem unlikely, activity at other receptors cannot be excluded. Keywords In vitro and in vivo metabolism • Metabolic stability • LC-HRMS/MS • Zebrafish larvae • In vitro µ-opioid receptor activity Electronic supplementary material The online version of this article (

Etazene induces developmental toxicity in vivo Danio rerio and in silico studies of new synthetic opioid derivative

“…Methylone is metabolized primarily by CYP2D6 with less contribution of CYP1A2 and 2C19 32 , mephedrone by CYP2D6 33 , 4F-MDMB-BINACA by CYP: 1A2, 2C19, 3A4 11 . Recently CYP3A4 and CYP2D6 were found as enzymes involved in two fentanyl derivates, 4F-Cy-BAP and Fu-BAP, pathways of metabolism 9 .…”

“…The D. rerio model has been frequently used in studies of NPS, including behavioral assessment of opioid addiction, anxiety, memory, and toxicological and pharmacological targets 7 . Recently, the D. rerio model has been successfully used to identify metabolites for various NPS groups, including cannabinoids 8 , opioids 9 , and cathinones 10 . Comparing metabolic processes of D. rerio to humans, consistent results have been obtained, which may be the basis for replacing the existing in vitro methods, characterized by substantial limitations 11 .…”

In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances

“…The biological activity of 11 non-fentanyl opioid NPS was evaluated using two distinct, previously reported, cell-based receptor activation assays Vasudevan et al 2020). The sensitivity and specificity of these systems was previously evaluated using a wide range of opioids Vasudevan et al 2020) and the system has since been successfully applied in different studies (Blanckaert & Cannaert et al 2020;Cannaert & Ambach et al 2018;Cannaert et al 2020;Gampfer et al 2020). The assays are based on the functional complementation of a split nanoluciferase (NanoLuc Binary Technology®, Promega).…”

First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?

“…We previously found that various substituted benzylfentanyls activate MOR to only a very limited extent, with Emax values of less than 10% compared to hydromorphone. In stark contrast to brorphine, the potencies of these compounds were in the high nM to µM range (29). Furthermore, as opposed to these benzylfentanyls, brorphine is currently not covered by generic legislations targeting fentanyl analogues (13,14), exposing a potentially dangerous legislative loophole.…”